Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for CSBR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
April 30, 2026 -0.238M
January 31, 2026 -0.014M
October 31, 2025 -0.242M
July 31, 2025 -0.046M
April 30, 2025 -0.253M
January 31, 2025 -0.042M
October 31, 2024 -0.094M
July 31, 2024 0.00
April 30, 2024 0.111M
January 31, 2024 -0.126M
October 31, 2023 -0.153M
July 31, 2023 -0.668M
April 30, 2023 -0.76M
January 31, 2023 -0.754M
October 31, 2022 -0.604M
July 31, 2022 -0.754M
April 30, 2022 -0.506M
January 31, 2022 -0.405M
October 31, 2021 -0.566M
July 31, 2021 -0.907M
April 30, 2021 -0.834M
January 31, 2021 -1.203M
October 31, 2020 -0.506M
July 31, 2020 -0.626M
April 30, 2020 -1.527M
Date Value
January 31, 2020 -0.171M
October 31, 2019 0.227M
July 31, 2019 -0.749M
April 30, 2019 -0.141M
January 31, 2019 -0.207M
October 31, 2018 -0.275M
July 31, 2018 -0.211M
April 30, 2018 -0.209M
January 31, 2018 -0.075M
October 31, 2017 -0.032M
July 31, 2017 -0.91M
April 30, 2017 -0.585M
January 31, 2017 -0.151M
October 31, 2016 -0.013M
July 31, 2016 -0.017M
April 30, 2016 -0.146M
January 31, 2016 -0.132M
October 31, 2015 -0.015M
July 31, 2015 -0.029M
April 30, 2015 -0.03M
January 31, 2015 -0.013M
October 31, 2014 -0.038M
July 31, 2014 -0.033M
April 30, 2014 -0.07M
January 31, 2014 -0.088M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Medpace Holdings, Inc. -23.88M
Avantor, Inc. -37.30M
Personalis, Inc. 38.16M
Adaptive Biotechnologies Corp. -43.48M
10X Genomics, Inc. -7.735M